Portola Pharmaceuticals has entered into an exclusive worldwide license agreement with Novartis. Novartis will develop and commercialize Portola’s intravenous (i.v.) and oral P2Y12 ADP receptor antagonist, elinogrel, currently in Phase II as a potential anti-clotting medication. Elinogrel has shown potential to offer clinical improvements over current anti-clotting medications in helping patients avoid heart attacks and strokes, such as lowering the risk of ischemic events due to clot form...